Head-To-Head Comparison: Rani Therapeutics (RANI) versus The Competition

Rani Therapeutics (NASDAQ:RANI) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Rani Therapeutics to related businesses based on the strength of its dividends, earnings, institutional ownership, valuation, profitability, analyst recommendations and risk.

Risk and Volatility

Rani Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Rani Therapeutics’ rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Rani Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rani Therapeutics	$1.63 million	-$29.67 million	-2.09
Rani Therapeutics Competitors	$729.47 million	$11.46 million	-14.93

Rani Therapeutics’ rivals have higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Rani Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1	0	4	0	2.60
Rani Therapeutics Competitors	9904	15277	45625	1595	2.54

Rani Therapeutics currently has a consensus price target of $8.33, indicating a potential upside of 1,377.54%. As a group, “Biotechnology” companies have a potential upside of 98.35%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than its rivals.

Insider and Institutional Ownership

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Rani Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	-493.00%	-76.50%	-55.82%
Rani Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Summary

Rani Therapeutics beats its rivals on 7 of the 13 factors compared.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion. The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.